Incorporating LRP2, CUBN, Caveolin-1, GIPC1, and DAB2IP into biomarker-driven clinical trial design could enhance risk stratification in uveal melanoma and RB and support the development of prognostic signatures that distinguish aggressive from indolent disease. Here, GIPC1 is linked to uveal melanoma.